Biology of Blood and Marrow Transplantation
Volume 17, Issue 5 , Pages 717-722 , May 2011

Fludarabine-Based Conditioning Chemotherapy for Allogeneic Hematopoietic Stem Cell Transplantation in Acquired Severe Aplastic Anemia

Received 1 June 2010 ,Accepted 16 August 2010.

References 

  1. Armand P, Antin JH. Allogeneic stem cell transplantation for aplastic anemia. Biol Blood Marrow Transplant. 2007;13:505–516
  2. Storb R, Etzioni R, Anasetti C, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 1994;84:941–949
  3. George B, Mathews V, Viswabandya A, et al. Fludarabine and cyclophosphamide–based reduced-intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia. Bone Marrow Transplant. 2007;40:13–18
  4. Resnick IB, Aker M, Shapira MY, et al. Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen. Br J Haematol. 2006;133:649–654
  5. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–217
  6. National Cancer Institute. Common terminology criteria for adverse events, version 3.0 (CTCAE). Available from: http://ctep.cancer.gov/forms/CTCAEv3.pdf. Accessed November 2009.
  7. Kaplan EL, Meier P. Nonparametric estimation from incomplete data. J Am Stat Assoc. 1958;53:457–481
  8. Bacigalupo A. Treatment strategies for patients with severe aplastic anemia. Bone Marrow Transplant. 2008;42(Suppl 1):S42–S44
  9. Deeg HJ, Socié G, Schoch G, et al. Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood. 1996;87:386–392
  10. Issaragrisil S, Kaufman DW, Anderson T, et al. The epidemiology of aplastic anemia in Thailand. Blood. 2006;107:1299–1307
  11. Chun HG, Leyland JB, Cheson BD. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol. 1991;175–188
  12. Aljurf MD, Zaidi SZ, El Solh H, et al. Special issues related to hematopoietic SCT in the Eastern Mediterranean region and the first regional activity report. Bone Marrow Transplant. 2009;43:1–12
  13. Mahmoud HK, Fahmy OA, Kamel M, et al. Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 1999;24:355–358
  14. Kumar R, Prem S, Mahapatra M, et al. Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia. Bone Marrow Transplant. 2006;37:745–749
  15. Ambulkar I, Parikh PM, Saikia T. Successful allogeneic stem cell transplantation with fludarabine-based conditioning regimen in severe aplastic anemia. J Assoc Physicians India. 2003;51:715–716
  16. Gómez-Almaguer D, Vela-Ojeda J, Jaime-Pérez JC, et al. Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience. Am J Hematol. 2006;81:157–161
  17. Srinivasan R, Takahashi Y, McCoy JP, et al. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br J Haematol. 2006;33:305–314
  18. Kang HJ, Shin HY, Choi HS, et al. Fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia. Bone Marrow Transplant. 2004;34:939–943
  19. Gupta V, Ball SE, Yi QL, et al. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. Biol Blood Marrow Transplant. 2004;10:867–876
  20. Bacigalupo A, Locatelli F, Lanino E, et al. Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant. 2005;36:947–950
  21. Chan KW, Li CK, Worth LL, et al. A fludarabine-based conditioning regimen for severe aplastic anemia. Bone Marrow Transplant. 2001;27:125–128
  22. Maury S, Bacigalupo A, Anderlini P, et al. Improving outcome of patients older than 30 years receiving HLA-identical sibling HSCT for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica. 2009;94:1312–1315

 Financial disclosure: See Acknowledgments on page 722.

PII: S1083-8791(10)00352-6

doi: 10.1016/j.bbmt.2010.08.013

Biology of Blood and Marrow Transplantation
Volume 17, Issue 5 , Pages 717-722 , May 2011

Article Tools

* Image Usage & Resolution